Genesis Global Group
Genesis Drug Discovery & Development
GD3

You will now be redirected to the GD3 website

Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.

Learn more about GD3
Search

Biochemistry & Bioanalytical

Contact our Experts

Uveitis

Uveitis is a group of intraocular inflammatory eye diseases that can result in irreversible blindness and vision loss. The eye is considered immune privileged due to a distinct blood-retinal barrier, however, breakdown of this immune privileged status and blood-retinal barrier can occur, resulting in ocular inflammation known as uveitis.1 At GD3, we induce uveitis through an intravitreal injection of the inflammatory protein TNFα. Following disease induction, our scientific experts conduct a variety of study readouts to shed light on disease pathology and the effect of therapeutic candidates.

Animal SpeciesRabbit
Method of Induction Intravitreal injection of TNFα
Follow up Period 2- 6 Weeks
Route of intervention Topical (ocular), IVT, systemic
Readouts
  • Ophthalmologic examinations by board-certified veterinary ophthalmologist
  • Intraocular pressure
  • Electroretinograms
  • Optical coherence tomography
  • Draize scoring
  • Clinical observations
  • Clinical pathology
  • Food and water consumption
  • Body weights
  • Ocular tissue collection (including non-terminal aqueous and vitreous)
  • Bioanalysis (TA, biomarkers)
  • Histological analysis at terminal time point (H&E, IF, IHC, Evans Blue etc.)
Figure 1. Vertical, single line, wide field OCT scan of a rabbit retina.
Reference:
  • 1. Chan, C.-C. (2016). Animal models of Ophthalmic Diseases. Springer.

Learn more about